Skip Navigation


Rheumatology Advance Access originally published online on May 29, 2009
Rheumatology 2009 48(9):1021-1028; doi:10.1093/rheumatology/kep112
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/9/1021    most recent
kep112v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bansard, C.
Right arrow Articles by Le-Loët, X.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bansard, C.
Right arrow Articles by Le-Loët, X.
Related Collections
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Reviews

Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?

Carine Bansard1,2, Thierry Lequerré1,2,3,4, Maryvonne Daveau1,2,4, Olivier Boyer1,2, Francois Tron1,2,4, Jean-Philippe Salier1,2,4,{dagger}, Olivier Vittecoq1,2,3,4 and Xavier Le-Loët1,2,3,4

1Inserm, Unité 905, 2Institut Fédératif de Recherche Multidisciplinaire sur les Peptides 23, Institute for Biomedical Research, Faculté de Médecine–Pharmacie, University of Rouen, 3Department of Rheumatology, Rouen University Hospital and 4Consortium EGERIE, Paris, Rouen, France

Correspondence to: Thierry Lequerré, Department of Rheumatology, Rouen University Hospital, 76031 Rouen Cedex, France. E-mail: thierry.lequerre{at}chu-rouen.fr


  Abstract

This review briefly recapitulates the existing markers predictive of RA responsiveness to treatment, focusing on MTX alone or combined with a biologic. In addition to the demographic and clinical factors, an update is provided of the predictive biomarkers identified by large-scale gene and protein analyses that generated new insights into the ability of high-throughput analysis of biological systems to select new potential indicators. Among the large-scale analysis tools now available, pharmacogenetics and pharmacogenomics (including transcriptomic and proteomic approaches) have been shown to provide such new putative biomarkers of therapeutic responses.

KEY WORDS: Rheumatoid arthritis, Methotrexate, Biologics, Biomarkers predictive of response, Pharmacogenetics, Pharmacogenomics

{dagger}Deceased.

Submitted 5 October 2008; revised version accepted 2 April 2009.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.